TP53 and cancer: In summary, our findings lead us to conclude that in cancers such as TNBCs, in which there are no frequently recurrent driver mutations except for TP53, probably at least 4–5 variants are required to obtain a sufficiently high sensitivity of detection and association with tumor features at baseline.